6LZG

Structure of novel coronavirus spike receptor-binding domain complexed with its receptor ACE2

6LZG の概要

• エントリーDOI: 10.2210/pdb6lzg/pdb
• 分子名称: Angiotensin-converting enzyme 2, Spike protein S1, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (5 entities in total)
• 機能のキーワード: novel coronavirus, spike protein, receptor, viral protein
• 由来する生物種: Homo sapiens (Human); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 93502.21

構造登録者

Wang, Q.H.,Song, H.,Qi, J.X. (登録日: 2020-02-19, 公開日: 2020-03-18, 最終更新日: 2024-11-06)

主引用文献

Wang, Q.,Zhang, Y.,Wu, L.,Niu, S.,Song, C.,Zhang, Z.,Lu, G.,Qiao, C.,Hu, Y.,Yuen, K.Y.,Wang, Q.,Zhou, H.,Yan, J.,Qi, J.
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.
Cell, 181:894-904.e9, 2020

PubMed Abstract: The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus.

PubMed: 32275855
DOI: 10.1016/j.cell.2020.03.045

実験手法

X-RAY DIFFRACTION (2.5 Å)